InsiderPulseNo transactions found.
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Net sales | $1.40B+3.2% | $1.36B-3.9% | $1.42B-1.6% | $1.44B+9.6% | $1.31B |
| Cost of sales | $1.09B+8.4% | $1.00B-4.6% | $1.05B-5.0% | $1.11B+6.3% | $1.04B |
| Gross profit | $319.5M-11.2% | $359.9M-2.0% | $367.1M+9.5% | $335.3M+22.3% | $274.2M |
| Selling, general and administrative expenses | $235.0M-2.8% | $241.8M+3.6% | $233.3M+11.4% | $209.5M+3.4% | $202.6M |
| Operating income | $84.5M-28.5% | $118.1M-11.7% | $133.8M+6.4% | $125.8M+470.6% | $22.0M |
| Interest expense, net | $14.0M+126.9% | $6.2M-7.6% | $6.7M-12.9% | $7.7M+103.3% | $3.8M |
| Other (income) expense, net | -$7.0M-1016.9% | -$623K+70.2% | -$2.1M-238.6% | $1.5M-65.8% | $4.4M |
| Earnings before income taxes | $77.5M-31.2% | $112.6M-12.9% | $129.3M+10.8% | $116.6M+740.9% | $13.9M |
| Income tax expense | $23.3M-15.2% | $27.5M-7.1% | $29.6M+136.9% | $12.5M+20.5% | $10.4M |
| Net earnings | $54.1M-36.4% | $85.1M-14.6% | $99.6M-4.3% | $104.1M+2886.4% | $3.5M |
| Basic earnings per share (in usd per share) | $3K-35.0% | $4K-14.1% | $5K-3.8% | $5K+3278.6% | $140 |
| Diluted earnings per share (in usd per share) | $3K-35.2% | $4K-13.7% | $5K-2.8% | $5K+3214.3% | $140 |
| Weighted average basic shares outstanding (in shares) | $21.3M-2.0% | $21.7M-0.7% | $21.9M-0.6% | $22.0M-11.7% | $24.9M |
| Weighted average diluted shares outstanding (in shares) | $21.5M-1.7% | $21.9M-0.9% | $22.1M-1.4% | $22.4M-11.4% | $25.3M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Apogee Expands Architectural Glass Segment With Kalwall Buyout
Apogee Therapeutics lines up $1.3B strategic financing for zumilokibart program
Apogee Enterprises to acquire Kalwall for up to $115M
Apogee Enterprises to Acquire Kalwall Companies